MX375467B - Proceso para la preparacion de un compuesto de diariltiohidantoina. - Google Patents
Proceso para la preparacion de un compuesto de diariltiohidantoina.Info
- Publication number
- MX375467B MX375467B MX2017008179A MX2017008179A MX375467B MX 375467 B MX375467 B MX 375467B MX 2017008179 A MX2017008179 A MX 2017008179A MX 2017008179 A MX2017008179 A MX 2017008179A MX 375467 B MX375467 B MX 375467B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- diarylthiohydantoin compound
- compound
- diarylthiohydantoin
- intermediates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describen los procesos e intermedios para la preparación del compuesto (X), que se investiga actualmente para el tratamiento del cáncer de próstata. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094436P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/066356 WO2016100652A2 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017008179A MX2017008179A (es) | 2017-09-18 |
| MX375467B true MX375467B (es) | 2025-03-06 |
Family
ID=55168400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008179A MX375467B (es) | 2014-12-19 | 2015-12-17 | Proceso para la preparacion de un compuesto de diariltiohidantoina. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9688655B2 (es) |
| EP (4) | EP3372586A1 (es) |
| JP (2) | JP6681902B2 (es) |
| KR (1) | KR102586059B1 (es) |
| CN (2) | CN118638097A (es) |
| AR (1) | AR103228A1 (es) |
| AU (1) | AU2015364537B2 (es) |
| BR (1) | BR112017013113B1 (es) |
| CA (1) | CA2970937A1 (es) |
| CY (3) | CY1121684T1 (es) |
| DK (3) | DK3372585T3 (es) |
| EA (4) | EA201892486A1 (es) |
| ES (3) | ES2827549T3 (es) |
| HR (3) | HRP20220750T1 (es) |
| HU (2) | HUE042409T2 (es) |
| IL (1) | IL252843B2 (es) |
| LT (3) | LT3372585T (es) |
| MA (1) | MA41200B1 (es) |
| MD (1) | MD3233803T2 (es) |
| ME (1) | ME03420B (es) |
| MX (1) | MX375467B (es) |
| NZ (1) | NZ732766A (es) |
| PH (1) | PH12017501152B1 (es) |
| PL (3) | PL3233803T3 (es) |
| PT (3) | PT3372585T (es) |
| RS (3) | RS63455B1 (es) |
| SG (4) | SG11201704969QA (es) |
| SI (3) | SI3233803T1 (es) |
| SM (3) | SMT202200242T1 (es) |
| TR (1) | TR201904739T4 (es) |
| TW (4) | TWI689494B (es) |
| UA (1) | UA123201C2 (es) |
| WO (1) | WO2016100652A2 (es) |
| ZA (1) | ZA201704877B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3233823T1 (sl) * | 2014-12-19 | 2019-04-30 | Aragon Pharmaceuticals, Inc. | Postopki priprave spojine diariltiohidantoina |
| MX375467B (es) * | 2014-12-19 | 2025-03-06 | Aragon Pharmaceuticals Inc | Proceso para la preparacion de un compuesto de diariltiohidantoina. |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN113968815B (zh) * | 2020-07-24 | 2025-11-18 | 苏州科伦药物研究有限公司 | 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法 |
| EP4541786A3 (en) | 2020-09-04 | 2025-08-06 | Synthon B.V. | Improved process for preparation of apalutamide |
| AU2021382674A1 (en) | 2020-11-20 | 2023-06-22 | Amgen Inc. | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
| CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
| CN115572264B (zh) * | 2021-07-06 | 2025-12-05 | 山东新时代药业有限公司 | 一种恩杂鲁胺的制备方法 |
| CN115850233B (zh) * | 2021-09-24 | 2024-12-10 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
| CN116239536A (zh) * | 2021-12-08 | 2023-06-09 | 山东新时代药业有限公司 | 一种阿帕鲁胺中间体化合物 |
| CN117534652A (zh) * | 2022-08-02 | 2024-02-09 | 黄冈人福药业有限责任公司 | 一种阿帕他胺的制备方法 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN116332907A (zh) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | 一种无定形阿帕他胺的制备方法 |
| CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| EP2656841B1 (en) * | 2006-03-27 | 2016-08-10 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| US8461343B2 (en) * | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| SG190625A1 (en) * | 2008-05-16 | 2013-06-28 | Takeda California Inc | Glucokinase activators |
| EA019970B8 (ru) * | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Производные имидазолидиндиона |
| MX2012009453A (es) * | 2010-02-16 | 2012-11-23 | Aragon Pharmaceuticals Inc | Moduladores del receptor de androgenos y usos de los mismos. |
| PT2538785T (pt) * | 2010-02-24 | 2018-05-09 | Medivation Prostate Therapeutics Llc | Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína |
| KR101567958B1 (ko) * | 2011-03-10 | 2015-11-10 | 수조우 킨터 제약회사(주) | 안드로겐 수용체 길항제 및 이의 용도 |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2013148375A1 (en) * | 2012-03-29 | 2013-10-03 | Sangart, Inc. | Diaspirin crosslinked pegylated hemoglobin |
| JP6469092B2 (ja) * | 2013-05-29 | 2019-02-13 | ヒノバ ファーマシューティカルズ インコーポレイテッド | イミダゾリジンジオン化合物及び薬物組成物 |
| MX375467B (es) * | 2014-12-19 | 2025-03-06 | Aragon Pharmaceuticals Inc | Proceso para la preparacion de un compuesto de diariltiohidantoina. |
-
2015
- 2015-12-17 MX MX2017008179A patent/MX375467B/es active IP Right Grant
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 CN CN202410667649.2A patent/CN118638097A/zh active Pending
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-17 SM SM20220242T patent/SMT202200242T1/it unknown
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 CN CN201580069602.5A patent/CN107108507B/zh active Active
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 PH PH1/2017/501152A patent/PH12017501152B1/en unknown
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 SM SM20200618T patent/SMT202000618T1/it unknown
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en not_active Ceased
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active Active
- 2015-12-17 SM SM20190208T patent/SMT201900208T1/it unknown
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 CA CA2970937A patent/CA2970937A1/en active Pending
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 IL IL252843A patent/IL252843B2/en unknown
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es active IP Right Grant
-
2017
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
-
2022
- 2022-06-10 CY CY20221100408T patent/CY1125243T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375467B (es) | Proceso para la preparacion de un compuesto de diariltiohidantoina. | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| MX383748B (es) | Procesos para la preparación de un compuesto de diariltiohidantoína. | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| MY184870A (en) | Immunomodulators | |
| LT3455258T (lt) | Odos vėžio gydymo būdai, įvedant pd-1 inhibitorių | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
| MX2017002609A (es) | Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso. | |
| MX380240B (es) | Preparación de piperidin-4-carbotioamida. | |
| MX390571B (es) | Metodos para tratamiento de cancer de ovario. | |
| AU2016902922A0 (en) | Methods of Treating Cancer (I) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |